A Glimpse Into The Expert Outlook On Sarepta Therapeutics Through 9 Analysts
Portfolio Pulse from Benzinga Insights
Nine analysts have provided varied opinions on Sarepta Therapeutics (NASDAQ:SRPT) over the past quarter, with a mix of bullish, somewhat bullish, and indifferent ratings. The average 12-month price target has increased to $162.56. Key analysts have maintained, raised, or lowered their ratings and price targets, reflecting their responses to recent developments. Sarepta Therapeutics has shown strong financial performance with significant revenue growth, high net margin, and strong ROE and ROA.
June 14, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have mixed views on Sarepta Therapeutics with an average 12-month price target of $162.56, reflecting a slight increase. The company's strong financial performance, including significant revenue growth and high net margin, supports a positive outlook.
The mixed analyst ratings, combined with a slight increase in the average price target and strong financial performance metrics, suggest a positive short-term impact on SRPT's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100